WO2022016375A1 - 异位子宫内膜识别多肽及其衍生物和应用 - Google Patents
异位子宫内膜识别多肽及其衍生物和应用 Download PDFInfo
- Publication number
- WO2022016375A1 WO2022016375A1 PCT/CN2020/103288 CN2020103288W WO2022016375A1 WO 2022016375 A1 WO2022016375 A1 WO 2022016375A1 CN 2020103288 W CN2020103288 W CN 2020103288W WO 2022016375 A1 WO2022016375 A1 WO 2022016375A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- recognition
- ectopic endometrial
- modification
- product obtained
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 92
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 89
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 89
- 210000004696 endometrium Anatomy 0.000 title claims abstract description 6
- 201000009273 Endometriosis Diseases 0.000 claims abstract description 23
- 230000002357 endometrial effect Effects 0.000 claims description 46
- 230000004048 modification Effects 0.000 claims description 28
- 238000012986 modification Methods 0.000 claims description 28
- 239000000523 sample Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000002372 labelling Methods 0.000 claims description 8
- 239000007850 fluorescent dye Substances 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 238000009007 Diagnostic Kit Methods 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000000975 dye Substances 0.000 claims description 4
- 230000026731 phosphorylation Effects 0.000 claims description 4
- 238000006366 phosphorylation reaction Methods 0.000 claims description 4
- 239000003504 photosensitizing agent Substances 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 230000021736 acetylation Effects 0.000 claims description 2
- 238000006640 acetylation reaction Methods 0.000 claims description 2
- 238000005576 amination reaction Methods 0.000 claims description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 2
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims description 2
- 229960004657 indocyanine green Drugs 0.000 claims description 2
- 230000000155 isotopic effect Effects 0.000 claims description 2
- 230000011987 methylation Effects 0.000 claims description 2
- 238000007069 methylation reaction Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 2
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 claims description 2
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 238000010791 quenching Methods 0.000 claims description 2
- 230000000171 quenching effect Effects 0.000 claims description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- -1 small molecule compound Chemical class 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 6
- 230000003902 lesion Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 238000010171 animal model Methods 0.000 abstract description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000001540 azides Chemical group 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Definitions
- the invention belongs to the field of medical cell biology, and relates to an ectopic endometrial recognition polypeptide and its derivatives and applications.
- Endometriosis is a gynecological disease formed by the attachment and growth of active cells in the endometrial tissue outside the body's endometrium. Studies estimate that as of 2015, more than 10 million people worldwide were affected. About 6-10% of women are affected by it. The most common sites of disease are the ovaries, fallopian tubes, and the tissues surrounding the uterus and ovaries. The main symptoms are pelvic pain and infertility. The cause of its pathogenesis is not fully understood. The endometriosis area can ooze blood leading to inflammation and scarring. Diagnosis is usually based on symptoms combined with medical imaging, with biopsy being the most reliable method of diagnosis. There is no cure for endometriosis, but many treatments can improve its symptoms. Endometriosis is often misdiagnosed due to the lack of specific diagnostic markers. Therefore, it is extremely valuable to find specific diagnostic identifiers for this intractable disease.
- the purpose of the present invention is to provide an ectopic endometrial recognition polypeptide and its derivatives and applications.
- One aspect of the present invention provides an ectopic endometrial recognition polypeptide, comprising a combination of one or more of the following sequences,
- the purity of the polypeptide is 50-100%.
- the purity of the polypeptide is 90-95%.
- Another aspect of the present invention provides a derivative of any of the above-mentioned ectopic endometrial-recognition polypeptides, wherein the derivative is a product obtained by modifying the terminal or side chain of the ectopic endometrial-recognition polypeptide, Or the product obtained by the labeling and modification of the ectopic endometrial recognition polypeptide with the fluorescent group, or the product obtained by the isotopic labeling of the ectopic endometrial recognition polypeptide, or the product obtained by the phosphorylation modification of the ectopic endometrial recognition polypeptide, Or the product obtained by cyclization modification based on disulfide bond of ectopic endometrial recognition polypeptide, or the product obtained by biotin labeling of ectopic endometrial recognition polypeptide, or the modification of ectopic endometrial recognition polypeptide by photosensitizer
- terminal or side chain modification of the ectopic endometrial recognition polypeptide includes but is not limited to N-terminal acetylation modification and C-terminal amination modification.
- the fluorescent dyes used in the labeling modification of the fluorescent group by the ectopic endometrial recognition polypeptide include but are not limited to FITC, Rhodamine, Cy3, Cy5, Cy5.5, Cy7, and the modification is used for the purpose of fluorescence detection. .
- polypeptide identified ectopic endometrial isotopically labeled isotopically used include, but are not limited to 13 C, the modified for tracking purposes.
- the phosphorylation modification of the ectopic endometrial recognition polypeptide includes but is not limited to p-Ser, p-Thr, and p-Tyr.
- the ectopic endometrial recognition polypeptide is labeled with biotin for the purpose of localization detection and the like.
- the ectopic endometrial recognition polypeptide is modified with a photosensitizer, so as to facilitate the preparation of a photosensitizer.
- the ectopic endometrial recognition polypeptide is modified with azide, which is beneficial to the secondary ligation reaction.
- the ectopic endometrial recognition polypeptide is PEG-modified for preparation of a drug carrier.
- the ectopic endometrial recognition polypeptide can be synthesized independently by general organic chemistry laboratory conditions, or industrially synthesized by conventional commercial reagent companies, that is, the polypeptide is synthesized by the solid-phase method, and the condensation reaction between different amino acids on the resin can be carried out. Achieves the synthesis of directional amino acid chains.
- the desired modification group is applied after the amino acid is linked.
- Another aspect of the present invention provides the use of any one of the above-mentioned polypeptides or any of the above-mentioned derivatives in the preparation of a medicament for diagnosing and/or treating endometriosis.
- Another aspect of the present invention provides a pharmaceutical composition for diagnosing and/or treating endometriosis, comprising any of the above-mentioned polypeptides or any of the above-mentioned derivatives.
- the ectopic endometrial recognition polypeptide and its derivatives can be combined with conventional organic chemical methods on a diagnostic and/or therapeutic carrier to exert application value based on the specific recognition function, thereby obtaining disease intervention tools that can be used for diagnosis and treatment.
- polypeptide probe adopts any of the above-mentioned polypeptide sequences or any of the above-mentioned derivatives, and reacts it with a fluorescent dye through conventional organic chemistry (such as EDC method reaction ligation) combined.
- the fluorescent dyes are selected from dyes with fluorescent groups in the near-infrared region, preferably, the dyes with fluorescent groups in the near-infrared region include but are not limited to Cy5, Cy7, and indocyanine green.
- Another aspect of the present invention provides an application of the above-mentioned polypeptide probe in the preparation of a diagnostic kit for endometriosis.
- Another aspect of the present invention provides a diagnostic kit for endometriosis, comprising any of the polypeptide probes described above.
- the identification polypeptide provided by the present invention can be used for the purpose of diagnosis and treatment of endometriosis.
- the recognition polypeptide provided by the present invention can be used as a targeted modification polypeptide to enhance the targeting and therapeutic properties of drugs and drug carriers.
- the identification polypeptide provided by the present invention has wide application prospects and low cost because of its short polypeptide size and easy to be synthesized and modified.
- the multivariate derivative candidate polypeptide provided by the present invention provides a broad selection strategy of diagnostic and therapeutic compounds or drugs for its practical application.
- the polypeptide molecule provided by the present invention can specifically identify ectopic endometrial lesions, and provides a specific identification tool for the diagnosis and treatment of patients with endometriosis. Due to the conservation and specificity of the sequence, the present invention is suitable for various basic clinical researches and applications of human endometriosis disease, and is also suitable for use as a research tool in endometriosis modeling experimental animals.
- FIG. 1 is a graph of fluorescence signal detection at a lesion in an embodiment of the present invention.
- the present invention takes the polypeptide sequence described in SEQ ID No. 1 as an example.
- polypeptide sequence is industrially synthesized by a specialized polypeptide preparation company.
- the amino acid at the C-terminal is linked to the N-terminal.
- the amino acids are linked one by one, and then the crude peptide is precipitated and centrifuged with excess ether.
- the crude peptide is purified by HPLC, and finally , mass spectrometry analysis, liquid nitrogen quick freeze drying for use.
- This example provides a polypeptide probe, which uses the polypeptide sequence prepared in Example 1 and combines it with a fluorescent dye through a conventional organic chemical reaction.
- mice of C57 strain were purchased. After anesthesia, one side of the uterine tissue was taken, and 2 square millimeters of endometrial tissue was excised. The ectopic inoculation was performed on the abdominal mesentery, and then the abdominal wall muscles and skin were sutured. The entire surgical operation was fully sterilized, and the mice were kept for more than one month for use.
- Example 3 To the endometriosis mouse model prepared in Example 3, after resting for 1-2 months, and after the formation of ectopic lesions, the polypeptide probe prepared in Example 2 was injected into the tail vein, 24 Hours later, the ectopic endometrial tissue was sampled and fixed, frozen sectioned in the dark, and observed under a confocal microscope, and specific fluorescent signals were seen (as shown in Figure 1).
- identification polypeptide provided by the present application can be used for the purpose of diagnosis and treatment of endometriosis.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
一种异位子宫内膜识别多肽及其衍生物和应用，属于医学细胞生物学领域。所述异位子宫内膜识别多肽，包括以下序列中的一条或多条的组合，SEQ ID No.1，SEQ ID No.2，SEQ ID No.3，SEQ ID No.4，SEQ ID No.5，SEQ ID No.6。该类多肽分子可特异识别异位子宫内膜病灶组织，为子宫内膜异位症病患的诊疗提供了一种特异的识别工具。由于序列的保守性和特异性，其适用于人类子宫内膜异位症疾病的各种基础临床研究及应用，也适用于作为子宫内膜异位症造模实验动物中的研究工具。
Description
本发明属于医学细胞生物学领域，涉及一种异位子宫内膜识别多肽及其衍生物和应用。
子宫内膜异位症是指子宫内膜组织中的活性细胞在机体子宫内膜以外的位置附着生长而形成的一种妇科疾病。有研究估计截至2015年全球有一千多万人受到影响。女性中约有6-10％受其影响。最常见发病部位是在卵巢、输卵管、以及子宫与卵巢周围的组织上。主要症状是骨盆疼痛和不育。其发病原因尚不完全清楚。子宫内膜异位症区域会渗血导致炎症和瘢痕形成。诊断通常基于症状并结合医学影像学，活检是最可靠的诊断方法。子宫内膜异位症尚无治愈方法，但许多治疗方法可改善其症状。由于缺乏特异的诊断标志物，子宫内膜异位症通常会被误诊。因此，针对这一疑难杂症，寻找特异的诊断识别物是极具价值的。
发明内容
为了解决上述背景技术中所提出的问题，本发明的目的在于提供一种异位子宫内膜识别多肽及其衍生物和应用。
为了达到上述目的，本发明所采用的技术方案为：
本发明一方面提供了一种异位子宫内膜识别多肽，包括以下序列中的一条或多条的组合，
进一步地，所述多肽的纯度为50-100％。
更进一步地，所述多肽的纯度为90-95％。
本发明另一方面提供了一种上述任一所述的异位子宫内膜识别多肽的衍生物，所述的衍生物为异位子宫内膜识别多肽进行末端或侧链的修饰得到的产物，或异位子宫内膜识别多肽进行荧光基团的标记修饰得到的产物，或异位子宫内膜识别多肽进行同位素标记得到的产物，或异位子宫内膜识别多肽进行磷酸化修饰得到的产物，或异位子宫内膜识别多肽进行基于二硫键的环化修饰得到的产物，或异位子宫内膜识别多肽进行生物素的标记得到的产物，或异 位子宫内膜识别多肽进行光敏剂修饰得到的产物，或异位子宫内膜识别多肽进行叠氮修饰得到的产物，或异位子宫内膜识别多肽进行PEG修饰得到的产物，或异位子宫内膜识别多肽进行甲基化修饰得到的产物，或异位子宫内膜识别多肽进行荧光淬灭基团修饰得到的产物，或异位子宫内膜识别多肽进行蛋白偶联修饰得到的产物，或异位子宫内膜识别多肽进行小分子化合物修饰得到的产物。
进一步地，所述异位子宫内膜识别多肽进行末端或侧链的修饰包括但不限于N端乙酰化修饰，C端的胺化修饰。
进一步地，所述异位子宫内膜识别多肽进行荧光基团的标记修饰中所用的荧光染料包括但不限于FITC、Rhodamine、Cy3、Cy5、Cy5.5、Cy7，该修饰以便用于荧光检测目的。
进一步地，所述异位子宫内膜识别多肽进行同位素标记中所用的同位素包括但不限于
13C，该修饰用于追踪目的。
进一步地，所述异位子宫内膜识别多肽进行的磷酸化修饰包括但不限于p-Ser、p-Thr、p-Tyr。
进一步地，所述异位子宫内膜识别多肽进行生物素的标记，用于定位检测目的等。
进一步地，所述异位子宫内膜识别多肽进行光敏剂修饰，以便于制备光敏感制剂。
进一步地，所述异位子宫内膜识别多肽进行叠氮修饰，有利于次级的连接反应。
进一步地，所述异位子宫内膜识别多肽进行PEG修饰，用于药物载体制备。
所述的异位子宫内膜识别多肽可通过一般有机化学实验室条件自主合成，也可以通过常规的商业化试剂公司工业合成，即利用固相法合成多肽，在树脂上不同氨基酸之间缩合反应实现定向氨基酸链的合成。多肽的衍生物则在氨基酸完成连接后，施加所需的修饰基团。
本发明再一方面提供了一种上述任一所述的多肽或者上述任一所述的衍生物在制备诊断和/或治疗子宫内膜异位症的药物中的应用。
本发明再一方面提供了一种诊断和/或治疗子宫内膜异位症的药物组合物，包括上述任一所述的多肽或者上述任一所述的衍生物。所述的异位子宫内膜识别多肽及其衍生物可通过常规有机化学方法结合于诊断和/或治疗载体上发挥特异识别功能基础上的应用价值，得到可用于诊疗的疾病干预工具。
本发明再一方面提供了一种多肽探针，所述多肽探针采用上述任一所述的多肽序列或者上述任一所述的衍生物，将其与荧光染料通过常规的有机化学反应(如EDC方法反应连接)结合制得。
进一步地，所述荧光染料选自具有近红外区荧光基团的染料，优选地，所述具有近红外 区荧光基团的染料包括但不限于Cy5、Cy7、吲哚菁绿。
本发明再一方面提供了一种上述所述的多肽探针在制备子宫内膜异位症诊断试剂盒中的应用。
本发明再一方面提供了一种子宫内膜异位症诊断试剂盒，包括上述任一所述的多肽探针。
本发明的有益效果：
(1)本发明提供的识别多肽，可用于子宫内膜异位症的诊疗目的。
(2)本发明提供的识别多肽，可作为靶向修饰多肽以增强药物及药物载体的靶向性和治疗性。
(3)本发明提供的识别多肽，由于其多肽短小易于合成修饰，因此其应用前景广泛，且成本低廉。
(4)本发明提供的多元的衍生物备选多肽，为其实际的应用提供了广泛的诊断治疗化合物或药物的选择策略。
(5)本发明提供的多肽分子可特异识别异位子宫内膜病灶组织，为子宫内膜异位症病患的诊疗提供了一种特异的识别工具。由于序列的保守性和特异性，本发明适用于人类子宫内膜异位症疾病的各种基础临床研究及应用，也适用于作为子宫内膜异位症造模实验动物中的研究工具。
图1为本发明实施例中病灶处荧光信号检测图。
为了更好地理解本发明的内容，下面结合具体实施方法对本发明内容作进一步说明，但本发明的保护内容不局限以下实施例。
本发明以SEQ ID No.1所述多肽序列为例。
实施例1：SEQ ID No.1所述多肽序列的制备
所述多肽序列由专门的多肽制备公司工业合成。
利用固相合成多肽法，从C端的氨基酸向N端进行链接，经过树脂活化、氨基酸链接、洗脱保护、检测步骤，逐个链接氨基酸，然后使用过量乙醚沉淀离心，对粗肽过HPLC纯化，最后，质谱分析，液氮速冷冻干备用。
实施例2：多肽探针的制备
本实施例提供一种多肽探针，采用实施例1制备得到的多肽序列，将其与荧光染料通过 常规的有机化学反应结合。
实施例3：子宫内膜异位症小鼠动物模型制备
购买7-8周的成年C57品系雌鼠，麻醉后，取一侧正位的子宫组织，切取2平方毫米大小含子宫内膜组织，异位接种于腹腔肠系膜部位，然后缝合腹壁肌肉及皮肤，整个手术操作过程充分消毒，将小鼠静养一个月以上备用。
实施例4：异位子宫内膜组织取样切片观察
对实施例3中制备的子宫内膜异位症小鼠模型，静养1-2月后，待其异位病灶形成后，对其进行尾静脉注射实施例2中所制备的多肽探针，24小时后，对异位子宫内膜组织取材固定，避光冰冻切片后，共聚焦显微镜下观察，可见特异的荧光信号(如图1所示)。
综上，本申请提供的识别多肽可用于子宫内膜异位症的诊疗目的。
以上所述仅为本发明的具体实施方式，不是全部的实施方式，本领域普通技术人员通过阅读本发明说明书而对本发明技术方案采取的任何等效的变换，均为本发明的权利要求所涵盖。
Claims (10)
- 一种异位子宫内膜识别多肽，其特征在于，包括以下序列中的一条或多条的组合，
- 根据权利要求1所述的多肽，其特征在于，所述多肽的纯度为50-100％，优选地，所述多肽的纯度为90-95％。
- 权利要求1-2任一项所述的异位子宫内膜识别多肽的衍生物，其特征在于，所述的衍生物为异位子宫内膜识别多肽进行末端或侧链的修饰得到的产物，或异位子宫内膜识别多肽进行荧光基团的标记修饰得到的产物，或异位子宫内膜识别多肽进行同位素标记得到的产物，或异位子宫内膜识别多肽进行磷酸化修饰得到的产物，或异位子宫内膜识别多肽进行基于二硫键的环化修饰得到的产物，或异位子宫内膜识别多肽进行生物素的标记得到的产物，或异位子宫内膜识别多肽进行光敏剂修饰得到的产物，或异位子宫内膜识别多肽进行叠氮修饰得到的产物，或异位子宫内膜识别多肽进行PEG修饰得到的产物，或异位子宫内膜识别多肽进行甲基化修饰得到的产物，或异位子宫内膜识别多肽进行荧光淬灭基团修饰得到的产物，或异位子宫内膜识别多肽进行蛋白偶联修饰得到的产物，或异位子宫内膜识别多肽进行小分子化合物修饰得到的产物。
- 根据权利要求3所述的衍生物，其特征在于，所述异位子宫内膜识别多肽进行末端或侧链的修饰包括N端乙酰化修饰，C端的胺化修饰；优选地，所述异位子宫内膜识别多肽进行荧光基团的标记修饰中所用的荧光染料包括FITC、Rhodamine、Cy3、Cy5、Cy5.5、Cy7；优选地，所述异位子宫内膜识别多肽进行同位素标记中所用的同位素包括 13C；优选地，所述异位子宫内膜识别多肽进行的磷酸化修饰包括p-Ser、p-Thr、p-Tyr。
- 权利要求1-2任一项所述的多肽或者权利要求3-4任一项所述的衍生物在制备诊断和/或治疗子宫内膜异位症的药物中的应用。
- 一种诊断和/或治疗子宫内膜异位症的药物组合物，其特征在于，包括权利要求1-2任一项所述的多肽或者权利要求3-4任一项所述的衍生物。
- 一种多肽探针，其特征在于，所述多肽探针采用权利要求1-2任一项所述的多肽或者权利要求3-4任一项所述的衍生物，将其与荧光染料通过常规的有机化学反应结合制得。
- 根据权利要求7所述的多肽探针，其特征在于，所述荧光染料选自具有近红外区荧光基团的染料；优选地，所述具有近红外区荧光基团的染料包括Cy5、Cy7、吲哚菁绿。
- 权利要求7或8所述的多肽探针在制备子宫内膜异位症诊断试剂盒中的应用。
- 一种子宫内膜异位症诊断试剂盒，其特征在于，包括权利要求7或8所述的多肽探针。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/103288 WO2022016375A1 (zh) | 2020-07-21 | 2020-07-21 | 异位子宫内膜识别多肽及其衍生物和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/103288 WO2022016375A1 (zh) | 2020-07-21 | 2020-07-21 | 异位子宫内膜识别多肽及其衍生物和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022016375A1 true WO2022016375A1 (zh) | 2022-01-27 |
Family
ID=79728404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2020/103288 WO2022016375A1 (zh) | 2020-07-21 | 2020-07-21 | 异位子宫内膜识别多肽及其衍生物和应用 |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2022016375A1 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117801091A (zh) * | 2023-12-28 | 2024-04-02 | 广东圆康再生医学科技开发有限公司 | 一种子宫内膜干细胞在子宫内膜修复中的应用 |
| CN117801091B (zh) * | 2023-12-28 | 2024-05-31 | 广东圆康再生医学科技开发有限公司 | 一种子宫内膜干细胞在子宫内膜修复中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107438625A (zh) * | 2015-02-26 | 2017-12-05 | Var2制药有限公司 | 使用嵌合抗原受体（cars）的胎盘样硫酸软骨素的免疫治疗靶向和使用具有分割蛋白结合系统的cars的癌症的免疫治疗靶向 |
| CN109387627A (zh) * | 2018-10-16 | 2019-02-26 | 中国科学院深圳先进技术研究院 | 一种基于胎盘样硫酸软骨素a的癌症筛查和早期诊断的试剂方法 |
| WO2019061648A1 (zh) * | 2017-09-28 | 2019-04-04 | 中国科学院深圳先进技术研究院 | 靶向胎盘样硫酸软骨素a的多肽、靶向递送系统及其制备方法和应用 |
| CN109568577A (zh) * | 2017-09-28 | 2019-04-05 | 中国科学院深圳先进技术研究院 | 一种用作光/声敏剂的靶向纳米颗粒及其制备方法和应用 |
-
2020
- 2020-07-21 WO PCT/CN2020/103288 patent/WO2022016375A1/zh active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107438625A (zh) * | 2015-02-26 | 2017-12-05 | Var2制药有限公司 | 使用嵌合抗原受体（cars）的胎盘样硫酸软骨素的免疫治疗靶向和使用具有分割蛋白结合系统的cars的癌症的免疫治疗靶向 |
| WO2019061648A1 (zh) * | 2017-09-28 | 2019-04-04 | 中国科学院深圳先进技术研究院 | 靶向胎盘样硫酸软骨素a的多肽、靶向递送系统及其制备方法和应用 |
| CN109568577A (zh) * | 2017-09-28 | 2019-04-05 | 中国科学院深圳先进技术研究院 | 一种用作光/声敏剂的靶向纳米颗粒及其制备方法和应用 |
| CN109387627A (zh) * | 2018-10-16 | 2019-02-26 | 中国科学院深圳先进技术研究院 | 一种基于胎盘样硫酸软骨素a的癌症筛查和早期诊断的试剂方法 |
Non-Patent Citations (2)
| Title |
|---|
| BAOZHEN ZHANG, LUNBO TAN, YAN YU, BAOBEI WANG, ZHILONG CHEN, JINYU HAN, MENGXIA LI, JIE CHEN, TIANXIA XIAO, BALAMURALI K AMBATI, L: "Placenta-specific drug delivery by trophoblast-targeted nanoparticles in mice", THERANOSTICS, vol. 8, no. 10, 1 January 2018 (2018-01-01), AU , pages 2765 - 2781, XP055625082, ISSN: 1838-7640, DOI: 10.7150/thno.22904 * |
| ZHANG BAOZHEN, LIANG RUIJING, ZHENG MINGBIN, CAI LINTAO, FAN XIUJUN: "Surface-Functionalized Nanoparticles as Efficient Tools in Targeted Therapy of Pregnancy Complications", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 20, no. 3642, pages 1 - 16, XP055888075, DOI: 10.3390/ijms20153642 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117801091A (zh) * | 2023-12-28 | 2024-04-02 | 广东圆康再生医学科技开发有限公司 | 一种子宫内膜干细胞在子宫内膜修复中的应用 |
| CN117801091B (zh) * | 2023-12-28 | 2024-05-31 | 广东圆康再生医学科技开发有限公司 | 一种子宫内膜干细胞在子宫内膜修复中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101669140B1 (ko) | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 | |
| US11890357B2 (en) | Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis | |
| CN108949147B (zh) | 一种分子影像探针及其应用 | |
| JP2003526622A (ja) | 老化防御効果を示すテトラペプチド、これを基にした薬理学的物質、及びその利用法 | |
| CN111615517B (zh) | Yeats抑制剂及其使用方法 | |
| WO2023104048A1 (zh) | 一种靶向脑瘤的多肽及其衍生物和应用 | |
| WO2023104052A1 (zh) | 一种跨血脑屏障的多肽及其衍生物和应用 | |
| CN113604214B (zh) | 一种高稳定性溶瘤肽荧光探针及其制备方法和应用 | |
| WO2015196944A1 (zh) | GnRH类似物-细胞毒分子缀合物、其制备方法及用途 | |
| CN109675015B (zh) | 化疗增敏多肽聚集体及其制备方法和应用 | |
| WO2022016375A1 (zh) | 异位子宫内膜识别多肽及其衍生物和应用 | |
| CN112442117A (zh) | 一种靶向卵泡刺激素受体的肿瘤成像与治疗探针及其制备方法与应用 | |
| TW201518319A (zh) | 人鬆馳素類似物、其藥物組成物及其在醫藥上的應用 | |
| WO2016078207A1 (zh) | 一种荧光共轭化合物及其应用 | |
| WO2022016751A1 (zh) | 一种子宫内膜异位症分子诊疗制剂及其制备方法和应用 | |
| CN113956331A (zh) | 异位子宫内膜识别多肽及其衍生物和应用 | |
| US20230203014A1 (en) | Novel fluorescent compounds for labeling tumor tissue | |
| RU2713151C1 (ru) | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения | |
| CN112592386A (zh) | 红光介导的核酸锚定型荧光探针及其制备方法和应用 | |
| WO2005030265A2 (en) | Optical imaging of endometriosis | |
| CN114452409B (zh) | 靶向c-Met的近红外荧光显像剂及其用途 | |
| WO2023213141A1 (zh) | 一种靶向卵巢的多肽及其衍生物和应用 | |
| WO2022016752A1 (zh) | 一种子宫内膜异位症病灶靶向纳米投递系统及其制备方法和应用 | |
| JP7497431B2 (ja) | ボツリヌストキシンまたはその塩を含む子宮内膜の血流量増進用組成物 | |
| WO2024031003A2 (en) | Grail-1 peptide products and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20946490 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20946490 Country of ref document: EP Kind code of ref document: A1 |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 03.07.2023) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20946490 Country of ref document: EP Kind code of ref document: A1 |